Home » Newsletters » BioWorld Science

BioWorld Science

April 23, 2012

View Archived Issues

Ranbaxy Laboratories presents new MMP-9 inhibitors

Novel anticancer compounds patented by Sanofi

New BTK inhibitor shows promise to treat B-cell malignancies

Advinus Therapeutics discloses new adenosine A2A receptor antagonists

New phase II results on quadruple therapy for treatment-resistant hepatitis C

Investigators in France rediscover traditional antimalarial agent

Astellas and Kaketsuken sign Japanese marketing agreement for vaccine

Novel PI3Kbeta inhibitor shows potential to treat PTEN-deficient tumors

Alder BioPharmaceuticals raises funds to support development of antibody therapeutics

CHMP confirms MAA opinion on Folotyn

Canadian study identifies potential new targets for breast cancer therapy

Novartis announces changes in fingolimod labeling in U.S. and E.U.

Array BioPharma discloses new agents for Alzheimer's disease

Novel products disclosed by Genentech and MRC Technology

Novel LDL-PLA(2) inhibitors patented by GSK

BTG reports outcome of second pivotal Varisolve study

AstraZeneca announces new acquisition plan

MicuRx completes phase I trial of next-generation oral antibiotic

Takeda announces CHMP opinion on Rienso

Japan's MHLW lifts condition on Humira approval

CHMP issues positive opinion on SkyePharma asthma therapy

CHMP recommends approval of Jakavi

European approval of Forxiga recommended

FDA extends review of linaclotide

Japan Tobacco and Torii report topline results from phase III GBA4-1 study

EMA committee maintains recommendation on Glybera

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...